Liminatus Pharma, Inc.
LIMN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $105.1K in total; no superinvestor holds it.
Other share classesLIMNW
13F holders, Q2 2026
Institutional positions in Liminatus Pharma, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −1 vs. Q1 2026
- Shares held
- 946.0K
- −529.5K (−35.9%) vs. Q1 2026
- Total value
- $105.1K
- −$148.7K (−58.6%) vs. Q1 2026
- New holders
- 4
- 1 more added
- Sold out
- 5
- 6 more reduced
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LIMN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $105.1K |
| Q1 2026 | 15 | $253.8K |
| Q4 2025 | 12 | $193.5K |
| Q3 2025 | 10 | $437.4K |
| Q2 2025 | 10 | $2.31M |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Liminatus Pharma, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Cygnus Capital Advisors, LLC | 329,333 | $36.0K | 0.02% | −20,667−5.9% | Reduced |
| XTX Topco Ltd | 221,839 | $24.5K | 0.00% | +221,839 | New |
| Geode Capital Management, LLC | 138,418 | $15.3K | 0.00% | +20,635+17.5% | Added |
| Citadel Advisors LLC | 56,089 | $6.19K | 0.00% | −621,429−91.7% | Reduced |
| Vanguard Capital Management LLC | 50,440 | $5.55K | 0.00% | 00.0% | Unchanged |
| Goldman Sachs Group Inc | 40,220 | $4.44K | 0.00% | +40,220 | New |
| StoneX Group Inc. | 26,058 | $3.93K | 0.00% | +26,058 | New |
| Vanguard Fiduciary Trust Co | 22,984 | $2.53K | 0.00% | 00.0% | Unchanged |
| State Street Corp | 19,000 | $2.10K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 16,730 | $1.84K | 0.00% | −37,848−69.3% | Reduced |
| JustInvest LLC | 13,148 | $1.45K | 0.00% | −21,558−62.1% | Reduced |
| Tower Research Capital LLC (TRC) | 7,093 | $783 | 0.00% | −474−6.3% | Reduced |
| Barclays PLC | 4,290 | $474 | 0.00% | +4,290 | New |
| BlackRock, Inc. | 313 | $35 | 0.00% | −12,941−97.6% | Reduced |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −71,318−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −27,468−100.0% | Sold out |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −22,039−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −6,769−100.0% | Sold out |
| Farther Finance Advisors, LLC | 0 | $0 | 0.00% | −14−100.0% | Sold out |